Physician profile
Stephen E Boatwright
NPI 1538157334
$3,002.09
in general payments reported to CMS, 2019-2025
25 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $179 · 2021: $362 · 2022: $616 · 2023: $693 · 2024: $145 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $18.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.45 |
| Education | $18.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $976.12 | 2019-2024 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $719.64 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Nevro Corp. | $211.15 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $134.50 | 2019-2020 | |
| Forte Bio-Pharma LLC | $131.64 | 2022-2023 | Prolate, Nalocet |
| Abbott Laboratories | $131.24 | 2019-2023 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.07 | 2019-2024 | Relistor |
| Nalu Medical, INC. | $69.43 | 2021-2023 | Nalu Neurostimulation System |
| Redhill Biopharma INC. | $55.97 | 2020-2021 | |
| Curonix LLC | $46.79 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Astrazeneca Pharmaceuticals Lp | $43.73 | 2019 | |
| Biodelivery Sciences International, INC. | $43.27 | 2021 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Pfizer INC. | $36.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $35.27 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $33.17 | 2022 | |
| Biotronik Nro, INC. | $23.07 | 2025 | Prospera |
| Virtus Pharmaceuticals LLC | $22.41 | 2023 | Levorphanol Tartrate |
| Abbvie INC. | $21.94 | 2022 | |
| Medtronic USA, INC. | $19.96 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.59 | 2025 | |
| Supernus Pharmaceuticals, INC. | $17.29 | 2019 | |
| Valinor Pharma, LLC | $15.61 | 2025 | Movantik |
| Shionogi INC | $15.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Boatwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.